

Jörg B Engel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5929181/publications.pdf>

Version: 2024-02-01

45
papers

1,570
citations

257101

24
h-index

301761

39
g-index

45
all docs

45
docs citations

45
times ranked

2211
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of an Antagonistic Analog of Growth Hormone-Releasing Hormone on Endometriosis in a Mouse Model and In Vitro. <i>Reproductive Sciences</i> , 2017, 24, 1503-1511.	1.1	7
2	Analysing Molecular Mechanism Related to Therapy- Resistance in In-vitro Models of Ovarian Cancer. , 2016, , .		0
3	Analysis of Clusterin and Clusterin Receptors in the Endometrium and Clusterin Levels in Cervical Mucus of Endometriosis. <i>Reproductive Sciences</i> , 2016, 23, 1371-1380.	1.1	7
4	Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2015, 291, 131-141.	0.8	7
5	GHRH-antagonists in TNBC. <i>Oncotarget</i> , 2015, 6, 1898-1899.	0.8	1
6	Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 141-147.	0.8	35
7	Ovarian epithelial tumors and reproductive factors: a systematic review. <i>Archives of Gynecology and Obstetrics</i> , 2013, 287, 1187-1204.	0.8	70
8	Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 905-914.	1.2	4
9	LHRH Analogs. , 2013, , 531-540.		3
10	Immune escape of AKT overexpressing ovarian cancer cells. <i>International Journal of Oncology</i> , 2013, 42, 1630-1635.	1.4	13
11	Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH). <i>Hormone Molecular Biology and Clinical Investigation</i> , 2012, 9, 87-94.	0.3	4
12	Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro. <i>Anti-Cancer Drugs</i> , 2012, 23, 426-436.	0.7	21
13	Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro. <i>Oncology Reports</i> , 2012, 28, 2023-2028.	1.2	35
14	Cervical endometriosis associated with malignant pleural mesothelioma mimicking cervical cancerâ€™Occamâ€™s razor or the â€œthird manâ€• <i>Fertility and Sterility</i> , 2011, 95, 1787.e5-1787.e7.	0.5	1
15	Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors. <i>Current Drug Delivery</i> , 2011, 8, 11-25.	0.8	61
16	Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers. <i>Archives of Gynecology and Obstetrics</i> , 2011, 283, 603-610.	0.8	26
17	Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1405-1418.	2.0	163
18	Macrophage migration inhibitory factor expression in cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 651-657.	1.2	29

#	ARTICLE	IF	CITATIONS
19	Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. <i>British Journal of Cancer</i> , 2010, 103, 693-700.	2.9	171
20	Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition. <i>International Journal of Oncology</i> , 2009, 35, 789-96.	1.4	26
21	Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 273-279.	1.1	29
22	Tubulin inhibitor AEZS 112 inhibits the growth of experimental human ovarian and endometrial cancers irrespective of caspase inhibition. <i>Oncology Reports</i> , 2009, 22, 361-7.	1.2	2
23	Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 33-43.	2.9	179
24	Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008, 141, 64-69.	0.5	28
25	Potential of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 1943-1946.	3.3	39
26	Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: A double-blind, placebo-controlled multicenter study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2007, 134, 225-232.	0.5	29
27	Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 157-167.	2.9	142
28	The GnRH antagonist cetrorelix: established indications and future potential. <i>Expert Review of Obstetrics and Gynecology</i> , 2007, 2, 431-440.	0.4	3
29	Targeted Therapy of Breast and Gynecological Cancers with Cytotoxic Analogues of Peptide Hormones. <i>Molecular Pharmaceutics</i> , 2007, 4, 652-658.	2.3	57
30	Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 10403-10407.	3.3	40
31	Analogues of Luteinizing Hormone-Releasing Hormone (LHRH) in Cancer. , 2006, , 421-427.		1
32	Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238. <i>International Journal of Cancer</i> , 2005, 114, 831-835.	2.3	11
33	Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. <i>Cancer</i> , 2005, 104, 1312-1321.	2.0	39
34	Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas. <i>Cancer</i> , 2005, 104, 2266-2274.	2.0	17
35	Effective Inhibition of Experimental Human Ovarian Cancers with a Targeted Cytotoxic Bombesin Analogue AN-215. <i>Clinical Cancer Research</i> , 2005, 11, 2408-2415.	3.2	23
36	Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. <i>Endocrine-Related Cancer</i> , 2005, 12, 999-1009.	1.6	36

#	ARTICLE	IF	CITATIONS
37	Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10628-10633.	3.3	21
38	Human Malignant Melanomas Express Receptors for Luteinizing Hormone Releasing Hormone Allowing Targeted Therapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogue. Cancer Research, 2005, 65, 5857-5863.	0.4	40
39	Inhibition of Growth of Experimental Human Endometrial Cancer by an Antagonist of Growth Hormone-Releasing Hormone. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3614-3621.	1.8	35
40	Receptors for Luteinizing Hormone Releasing Hormone Expressed on Human Renal Cell Carcinomas Can Be Used for Targeted Chemotherapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogues. Clinical Cancer Research, 2005, 11, 5549-5557.	3.2	36
41	Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207. Fertility and Sterility, 2005, 83, 1125-1133.	0.5	29
42	Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: Low induction of multidrug resistance proteins. European Journal of Cancer, 2005, 41, 1824-1830.	1.3	12
43	Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. European Journal of Cancer, 2005, 41, 2196-2202.	1.3	31
44	Inhibin B on the day of HCG-administration is a predictive factor for failure in assisted reproduction cycles. Archives of Gynecology and Obstetrics, 2003, 268, 278-280.	0.8	2
45	Inhibin A/B in HMG or recombinant FSH ovarian stimulation with cetorelix medication. Reproductive BioMedicine Online, 2001, 3, 104-108.	1.1	5